Tercica: Growing Small
This article was originally published in Start Up
Executive SummaryArmed with a powerful, in-licensed late-stage molecule from Genentech, two-and-a half-year-old Tercica is about a year away from entering the eminently reachable market for treating short-stature children, a potentially significant segment of a $750 million annual US market. But unlike many start-up in-licensers that seek niche indications for their lead programs, Tercica won't be able to fly under the radar of the competition.
You may also be interested in...
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.